Preventive Effects of Duloxetine Against Methamphetamine Induced Neurodegeneration and Motor Activity Disorder in Rat: Possible Role of CREB/BDNF Signaling Pathway
Authors:
Open Access
- 1 January 2019
- journal article
- research article
- Published by Wolters Kluwer Health in International Journal of Preventive Medicine
- Vol. 10 (1) , 195
Abstract
Background: The neuroprotective effects of duloxetine and neurodegenerative effects of methamphetamine have been shown in previous studies, but their exact mechanism remain unclear. In the current study it involved molecular mechanisms of neuroprotective effects of duloxetine against methamphetamine induced neurodegeneration were clarified. Methods: About 40 adult male rats randomly were divided to 5 groups. Group 1 and 2, as control and methamphetamine treated, received normal saline and methamphetamine (10 mg/kg) respectively. Groups 3, 4 and 5 concurrently treated with methamphetamine and duloxetine at doses of 10, 20 and 30 mg/kg respectively. All treatments were undertaken for 21 days. On day 22 Open Field Test (OFT) were used to examine the level of motor activity disturbance and anxiety in animals. After that hippocampus was isolated from each rat and oxidative, antioxidant, inflammatory factors and also level or expression of total and phosphorylated forms of CREB and P-CREB and BDNF proteins were measured. Results: Duloxetine in all mentioned doses could inhibit the effects of methamphetamine induced motor activity disturbance in MWM. Chronic abuse of methamphetamine could increase malondialdehyde (MDA), tumor necrosis factor-Alpha (TNF-α) and interleukine-1beta (IL-1β) while caused decreases in superoxide dismutase (SOD), glutathione peroxidase (GPx) and glutathione reductase (GR) activities and decreased CREB (both forms) and BDNF proteins, while duloxetine could prevent these malicious effects of methamphetamine. Conclusions: We conclude that P-CREB/BDNF signaling pathways might have critical role in duloxetine neuroprotective effects against methamphetamine induced neurodegeneration.Keywords
This publication has 31 references indexed in Scilit:
- Guidelines for reporting experiments involving animals: the ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Methamphetamine Self-Administration Is Associated with Persistent Biochemical Alterations in Striatal and Cortical Dopaminergic Terminals in the RatPLOS ONE, 2010
- Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trialInternational Clinical Psychopharmacology, 2007
- Mechanisms of methamphetamine-induced dopaminergic neurotoxicityThe AAPS Journal, 2006
- Duloxetine vs. placebo in patients with painful diabetic neuropathyPain, 2005
- Activity-Dependent Neuroprotection and cAMP Response Element-Binding Protein (CREB): Kinase Coupling, Stimulus Intensity, and Temporal Regulation of CREB Phosphorylation at Serine 133Journal of Neuroscience, 2005
- Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicityExperimental Neurology, 2004
- Duloxetine, 60 mg Once Daily, for Major Depressive DisorderThe Journal of Clinical Psychiatry, 2002
- Duloxetine in the Treatment of Major Depressive DisorderThe Journal of Clinical Psychiatry, 2002
- Association of Dopamine Transporter Reduction With Psychomotor Impairment in Methamphetamine AbusersAmerican Journal of Psychiatry, 2001